Thursday, July 9, 2015 - Attorneys handling national Xarelto lawsuit lawsuits which are among those consolidated as MDL No. 2592 announce the July Case Management Conference will take place today, July 9, 2015.* Counsel for Plaintiffs and Defendants have been meeting over the past month to negotiate a proposed Case Management Order No. 2, which was submitted last week, according to court documents. The proposed Case Management Order, which addresses matters related to discovery and bellweather trials, will be addressed at tomorrow‘s Status Conference, according to court documents.
Xarelto lawsuits that have been consolidated as Multidistrict Litigation No. 2592 Xarelto (Rivaroxaban) Products Liability Litigation now number over 500, according to court documents. Each of these Xarelto lawsuits was filed by a person or family member of a person who allegedly suffered severe internal bleeding as a result of taking Xarelto, a side effect which the lawsuits allege is more common and more severe than the drug‘s warning label indicates, according to court documents. Plaintiffs say that had they been properly warned about the alleged risk of severe internal bleeding, they would not have chosen to take Xarelto, according to court documents.
In June of 2013, Bayer and Janssen Pharmaceuticals received a written warning from the FDA stating the risk of severe internal bleeding had been understated on the product‘s packaging.** Federal regulators said the companies‘ marketing for Xarelto was "false or misleading" because it "minimizes the risks associated with Xarelto and makes a misleading claim". In short, plaintiffs allege the company overstated the usefulness of Xarelto and concealed the danger of internal bleeding, according to court documents.* The MDL is underway in U.S. District Court in the Eastern District of Louisiana.
Xarelto attorneys offer up-to-date Xarelto lawsuit news and safety information at their website, and also provide free Xarelto lawsuit case evaluation to persons who believe they may have grounds for a claim. If you or a loved one suffered from severe internal bleeding, a hemorrhagic stroke, or another serious health condition while taking Xarelto, you qualify for a no-cost, no-obligation case review. Xarelto attorneys are investigating inquiries for possible internal bleeding lawsuits.
The Onder Law Firm is renowned for its achievements in product and consumer safety litigation, with a strong track record of winning meaningful settlements for clients. The firm is nationally-renowned for its work on window blind strangulation, and has notable expertise in fighting on behalf of individuals against powerful corporations. Individuals and the family members of individuals who have suffered from internal bleeding and have taken Xarelto are eligible for a no-cost, no-obligation Xarelto lawsuit case review, and may contact the firm through its Xarelto Contingency Lawsuit website.
The Onder Law Firm also welcomes Xarelto lawsuit inquiries from other law firms, either to handle these inquiries or work as co-counsel.
About The Onder Law Firm
Onder, Shelton, O‘Leary & Peterson, LLC is a St. Louis based personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. Onder, Shelton, O‘Leary & Peterson has represented clients throughout the United States, and other firms throughout the nation often seek its experience and expertise on complex litigation. It is a recognized leader in products liability cases such as window blind cord strangulation and pharmaceutical litigation. The Onder Law Firms Xarelto attorneys provide information to the public at www.XareltoContingencyLawsuit.com.
*Xarelto (Rivaroxaban) Products Liability Litigation, MDL No. 2592, United States District Court, Eastern District of Louisiana